CGEM Stock Recent News

Shares have fallen by 40% since 2021 IPO was priced. I like management's unique approach of focusing on high-impact targets first and then determining the optimal modality after.

Cullinan Oncology's total cash and short-term investment is $611 million, up 94% from the previous quarter. The company's portfolio consists of eight product candidates that can significantly improve the quality of life of patients suffering from various types of cancer.

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Company management will participate in the following investor conferences:

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Officer, Jeff Trigilio, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 in Miami, FL and virtually.

Taiho Pharmaceutical Co Ltd will co-develop and co-commercialize Cullinan Oncology Inc (NASDAQ: CGEM) lead program, CLN-081/TAS6417. Under the agreement, Taiho will acquire Cullinan Oncology's subsidiary, Cullinan Pearl, which has worldwide rights outside of Japan to CLN-081/.